CIPRO XR SUMMARY
CIPRO XR (ciprofloxacin * extended-release tablets) contains ciprofloxacin, a synthetic broad-spectrum antimicrobial agent for oral administration. CIPRO XR tablets are coated, bilayer tablets consisting of an immediate-release layer and an erosion-matrix type controlled-release layer. The tablets contain a combination of two types of ciprofloxacin drug substance, ciprofloxacin hydrochloride and ciprofloxacin betaine (base). Ciprofloxacin hydrochloride is 1-cyclopropyl-6-fluoro-1, 4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid hydrochloride. It is provided as a mixture of the monohydrate and the sesquihydrate.
CIPRO XR is indicated only for the treatment of urinary tract infections, including acute uncomplicated pyelonephritis, caused by susceptible strains of the designated microorganisms as listed below. CIPRO XR and ciprofloxacin immediate-release tablets are not interchangeable. Please see DOSAGE AND ADMINISTRATION for specific recommendations.
Uncomplicated Urinary Tract Infections (Acute Cystitis) caused by
Escherichia coli, Proteus mirabilis, Enterococcus faecalis, or
Staphylococcus saprophyticus a.
Complicated Urinary Tract Infections caused by
Escherichia coli, Klebsiella pneumoniae, Enterococcus faecalis, Proteus mirabilis,
Pseudomonas aeruginosa a.
Acute Uncomplicated Pyelonephritis caused by
a Treatment of infections due to this organism in the organ system was studied in fewer than 10 patients.
THE SAFETY AND EFFICACY OF CIPRO XR IN TREATING INFECTIONS OTHER THAN URINARY TRACT INFECTIONS HAS NOT BEEN DEMONSTRATED. Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to ciprofloxacin. Therapy with CIPRO XR may be initiated before results of these tests are known; once results become available appropriate therapy should be continued. Culture and susceptibility testing performed periodically during therapy will provide information not only on the therapeutic effect of the antimicrobial agent but also on the possible emergence of bacterial resistance.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of CIPRO XR and other antibacterial drugs, CIPRO XR should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Media Articles Related to Cipro XR (Ciprofloxacin)
Finafloxacin for the treatment of urinary tract infections: results of a Phase 2 clinical study
Source: Urology / Nephrology News From Medical News Today [2015.09.21]
Results from a double-blind phase 2 clinical study show that finafloxacin was a more effective and safe option than ciprofloxacin for the treatment of complicated urinary tract infections and acute...
Published Studies Related to Cipro XR (Ciprofloxacin)
Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in
perianal fistula closure in Crohn's disease: a randomised, double-blind, placebo
controlled trial (ADAFI). 
disease (CD)... CONCLUSIONS: Combination therapy of adalimumab and ciprofloxacin is more
Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a
phase II randomised study. 
This phase II, randomised, double-blind, multicentre study (NCT00930982)
investigated the safety and efficacy of ciprofloxacin dry powder for inhalation
(DPI) in patients with non-cystic fibrosis bronchiectasis. Adults who were
culture positive for pre-defined potential respiratory pathogens (including
Pseudomonas aeruginosa and Haemophilus influenzae) were randomised to
ciprofloxacin DPI 32.5 mg or placebo administered twice daily for 28 days (with
56 days of follow-up).
Evaluation of the efficacy and safety of intravenous ciprofloxacin versus meropenem in the treatment of postoperative infection. [2011.10.19]
Therapeutic options for postoperative infection in gastrointestinal surgery are limited. To identify new treatment alternatives, the Japan Society for Surgical Infection conducted a multicenter prospective, randomized, controlled clinical trial comparing the efficacy of intravenous ciprofloxacin (CIP IV) and intravenous meropenem (MEM IV).
A multi-center randomized trial to assess the efficacy of gatifloxacin versus ciprofloxacin for the treatment of shigellosis in Vietnamese children. [2011.08]
CONCLUSIONS: We conclude that in Vietnam, where nalidixic acid resistant Shigellae are highly prevalent, ciprofloxacin and gatifloxacin are similarly effective for the treatment of acute shigellosis.
Pharmacokinetic interactions between ciprofloxacin and itraconazole in healthy male volunteers. [2011.04]
OBJECTIVE: To investigate the pharmacokinetic interaction between ciprofloxacin and itraconazole in healthy male volunteers... CONCLUSION: Ciprofloxacin decreases the metabolism of itraconazole, most likely through inhibition of CYP3A4. The dosage of itraconazole should be reduced and its therapeutic outcome should be monitored closely when these two agents are concomitantly administered. Copyright (c) 2011 John Wiley & Sons, Ltd.
Clinical Trials Related to Cipro XR (Ciprofloxacin)
Safety and Efficacy of Once-Daily Dosing of FoamOtic Cipro Compared to Twice-Daily Dosing of Ciloxan Ear Drops in Patients With Acute External Otitis [Completed]
The purpose of this study is to assess the Safety and Efficacy of Foam Otic Cipro (0. 3%
Ciprofloxacin Otic Foam), used once-daily for 7 days for the treatment of Acute Diffuse
Otitis Externa, compared to commercial ear drops used twice daily for 7 days.
Safety and Efficacy Study of Foam Otic Cipro Compared to a Standard Solution ( Ciloxan - Alcon Labs ) to Treat Acute Otitis Externa [Completed]
The purpose of this study is to assess the Safety and Efficacy of Foam Otic Cipro, a novel
medication developed to treat Acute Diffuse Otitis Externa of bacterial origin.
The working hypothesis is that Foam Otic Cipro is as effective as registered ear drops.
Study to Evaluate the Safety and Efficacy of Ciprofloxacin (Inhaled) in Patients With Cystic Fibrosis [Completed]
To evaluate the change in forced expiratory volume (FEV1) from baseline to Day 28-30 between
Cipro Inhale-treated and placebo-treated subjects after a 4-week treatment period.
A Comparative Study Between Two Formulations of the Ciprofloxacin Hydrochloride + Hydrocortisone Otic Suspension [Completed]
The objective of this study is to compare the efficacy and safety profiles of the test
product containing 2 mg/mL ciprofloxacin hydrochloride associated with 10 mg/mL of
hydrocortisone with the reference product Cipro HC®, in patients with acute otitis externa.
Evaluation of Cipro Inhale in Patients With Non-cystic Fibrosis Bronchiectasis [Completed]
The purpose of this study is to find out if bacterial load in the airways can be reduced
after inhalation of ciprofloxacin for 28 days.
Reports of Suspected Cipro XR (Ciprofloxacin) Side Effects
Cystitis Haemorrhagic (5),
Blood Triglycerides Increased (5), more >>
Page last updated: 2015-09-21